Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer

Masafumi Yamaguchi, Gouji Toyokawa, Taro Ohba, Tomonari Sasaki, Takuro Kometani, Motoharu Hamatake, Fumihiko Hirai, Kenichi Taguchi, Takeharu Yamanaka, Takashi Seto, Mitsuhiro Takenoyama, Kenji Sugio, Yukito Ichinose

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background Concurrent chemoradiotherapy using S-1 containing tegafur, an oral 5-FU prodrug, plus cisplatin has been reported to show promising efficacy against locally advanced non-small cell lung cancer with acceptable toxicity. The purpose of this study is to assess the impact of this induction treatment followed by surgery on survival for those patients. Methods Potentially resectable locally advanced non-small cell lung cancer patients were eligible. The concurrent phase consisted of S-1 (orally at 40 mg/m twice a day on days 1 to 14 and 22 to 36) and cisplatin (60 mg/m on days 1 and 22) with radiation of 40 Gy/20 fractions beginning on day 1 followed by surgical resection. Results Forty-two consecutive patients, between June 2005 and February 2011, were retrospectively analyzed. The median age was 59 (42 to 77) years, there were 34 males and 8 females, 26 cStage IIIA and 16 IIIB, each 21 adenocarcinomas and others. There were 26 partial responses and 16 stable disease cases after current induction treatment without uncontrollable toxicity. Of the 42 patients, 39 underwent surgical resection; 27 underwent a lobectomy and 12 pneumonectomies. One patient died due to thoracic empyema 65 days after surgery. The median follow-up time was 32.0 months. Three- and 5-year disease-free survival rates in all 39 resected patients were 52.0% and 44.0%, respectively, and 3- and 5-year overall survival rates were 77.4% and 61.7%, respectively. Conclusions Concurrent chemoradiotherapy using S-1 plus cisplatin followed by surgery may provide a better prognosis for locally advanced non-small cell lung cancer patients. Further prospective clinical investigation should be required.

Original languageEnglish
Pages (from-to)1783-1789
Number of pages7
JournalAnnals of Thoracic Surgery
Volume96
Issue number5
DOIs
Publication statusPublished - Nov 1 2013

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Cisplatin
Survival Rate
Pleural Empyema
Tegafur
Radiation Dosage
Pneumonectomy
Prodrugs
Ambulatory Surgical Procedures
S Phase
Fluorouracil
Disease-Free Survival
Adenocarcinoma
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer. / Yamaguchi, Masafumi; Toyokawa, Gouji; Ohba, Taro; Sasaki, Tomonari; Kometani, Takuro; Hamatake, Motoharu; Hirai, Fumihiko; Taguchi, Kenichi; Yamanaka, Takeharu; Seto, Takashi; Takenoyama, Mitsuhiro; Sugio, Kenji; Ichinose, Yukito.

In: Annals of Thoracic Surgery, Vol. 96, No. 5, 01.11.2013, p. 1783-1789.

Research output: Contribution to journalArticle

Yamaguchi, M, Toyokawa, G, Ohba, T, Sasaki, T, Kometani, T, Hamatake, M, Hirai, F, Taguchi, K, Yamanaka, T, Seto, T, Takenoyama, M, Sugio, K & Ichinose, Y 2013, 'Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer', Annals of Thoracic Surgery, vol. 96, no. 5, pp. 1783-1789. https://doi.org/10.1016/j.athoracsur.2013.06.036
Yamaguchi, Masafumi ; Toyokawa, Gouji ; Ohba, Taro ; Sasaki, Tomonari ; Kometani, Takuro ; Hamatake, Motoharu ; Hirai, Fumihiko ; Taguchi, Kenichi ; Yamanaka, Takeharu ; Seto, Takashi ; Takenoyama, Mitsuhiro ; Sugio, Kenji ; Ichinose, Yukito. / Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer. In: Annals of Thoracic Surgery. 2013 ; Vol. 96, No. 5. pp. 1783-1789.
@article{445436fc9f5744449da9696ddc1dd320,
title = "Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer",
abstract = "Background Concurrent chemoradiotherapy using S-1 containing tegafur, an oral 5-FU prodrug, plus cisplatin has been reported to show promising efficacy against locally advanced non-small cell lung cancer with acceptable toxicity. The purpose of this study is to assess the impact of this induction treatment followed by surgery on survival for those patients. Methods Potentially resectable locally advanced non-small cell lung cancer patients were eligible. The concurrent phase consisted of S-1 (orally at 40 mg/m{\^A} twice a day on days 1 to 14 and 22 to 36) and cisplatin (60 mg/m{\^A} on days 1 and 22) with radiation of 40 Gy/20 fractions beginning on day 1 followed by surgical resection. Results Forty-two consecutive patients, between June 2005 and February 2011, were retrospectively analyzed. The median age was 59 (42 to 77) years, there were 34 males and 8 females, 26 cStage IIIA and 16 IIIB, each 21 adenocarcinomas and others. There were 26 partial responses and 16 stable disease cases after current induction treatment without uncontrollable toxicity. Of the 42 patients, 39 underwent surgical resection; 27 underwent a lobectomy and 12 pneumonectomies. One patient died due to thoracic empyema 65 days after surgery. The median follow-up time was 32.0 months. Three- and 5-year disease-free survival rates in all 39 resected patients were 52.0{\%} and 44.0{\%}, respectively, and 3- and 5-year overall survival rates were 77.4{\%} and 61.7{\%}, respectively. Conclusions Concurrent chemoradiotherapy using S-1 plus cisplatin followed by surgery may provide a better prognosis for locally advanced non-small cell lung cancer patients. Further prospective clinical investigation should be required.",
author = "Masafumi Yamaguchi and Gouji Toyokawa and Taro Ohba and Tomonari Sasaki and Takuro Kometani and Motoharu Hamatake and Fumihiko Hirai and Kenichi Taguchi and Takeharu Yamanaka and Takashi Seto and Mitsuhiro Takenoyama and Kenji Sugio and Yukito Ichinose",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.athoracsur.2013.06.036",
language = "English",
volume = "96",
pages = "1783--1789",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer

AU - Yamaguchi, Masafumi

AU - Toyokawa, Gouji

AU - Ohba, Taro

AU - Sasaki, Tomonari

AU - Kometani, Takuro

AU - Hamatake, Motoharu

AU - Hirai, Fumihiko

AU - Taguchi, Kenichi

AU - Yamanaka, Takeharu

AU - Seto, Takashi

AU - Takenoyama, Mitsuhiro

AU - Sugio, Kenji

AU - Ichinose, Yukito

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background Concurrent chemoradiotherapy using S-1 containing tegafur, an oral 5-FU prodrug, plus cisplatin has been reported to show promising efficacy against locally advanced non-small cell lung cancer with acceptable toxicity. The purpose of this study is to assess the impact of this induction treatment followed by surgery on survival for those patients. Methods Potentially resectable locally advanced non-small cell lung cancer patients were eligible. The concurrent phase consisted of S-1 (orally at 40 mg/m twice a day on days 1 to 14 and 22 to 36) and cisplatin (60 mg/m on days 1 and 22) with radiation of 40 Gy/20 fractions beginning on day 1 followed by surgical resection. Results Forty-two consecutive patients, between June 2005 and February 2011, were retrospectively analyzed. The median age was 59 (42 to 77) years, there were 34 males and 8 females, 26 cStage IIIA and 16 IIIB, each 21 adenocarcinomas and others. There were 26 partial responses and 16 stable disease cases after current induction treatment without uncontrollable toxicity. Of the 42 patients, 39 underwent surgical resection; 27 underwent a lobectomy and 12 pneumonectomies. One patient died due to thoracic empyema 65 days after surgery. The median follow-up time was 32.0 months. Three- and 5-year disease-free survival rates in all 39 resected patients were 52.0% and 44.0%, respectively, and 3- and 5-year overall survival rates were 77.4% and 61.7%, respectively. Conclusions Concurrent chemoradiotherapy using S-1 plus cisplatin followed by surgery may provide a better prognosis for locally advanced non-small cell lung cancer patients. Further prospective clinical investigation should be required.

AB - Background Concurrent chemoradiotherapy using S-1 containing tegafur, an oral 5-FU prodrug, plus cisplatin has been reported to show promising efficacy against locally advanced non-small cell lung cancer with acceptable toxicity. The purpose of this study is to assess the impact of this induction treatment followed by surgery on survival for those patients. Methods Potentially resectable locally advanced non-small cell lung cancer patients were eligible. The concurrent phase consisted of S-1 (orally at 40 mg/m twice a day on days 1 to 14 and 22 to 36) and cisplatin (60 mg/m on days 1 and 22) with radiation of 40 Gy/20 fractions beginning on day 1 followed by surgical resection. Results Forty-two consecutive patients, between June 2005 and February 2011, were retrospectively analyzed. The median age was 59 (42 to 77) years, there were 34 males and 8 females, 26 cStage IIIA and 16 IIIB, each 21 adenocarcinomas and others. There were 26 partial responses and 16 stable disease cases after current induction treatment without uncontrollable toxicity. Of the 42 patients, 39 underwent surgical resection; 27 underwent a lobectomy and 12 pneumonectomies. One patient died due to thoracic empyema 65 days after surgery. The median follow-up time was 32.0 months. Three- and 5-year disease-free survival rates in all 39 resected patients were 52.0% and 44.0%, respectively, and 3- and 5-year overall survival rates were 77.4% and 61.7%, respectively. Conclusions Concurrent chemoradiotherapy using S-1 plus cisplatin followed by surgery may provide a better prognosis for locally advanced non-small cell lung cancer patients. Further prospective clinical investigation should be required.

UR - http://www.scopus.com/inward/record.url?scp=84887114988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887114988&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2013.06.036

DO - 10.1016/j.athoracsur.2013.06.036

M3 - Article

C2 - 23998404

AN - SCOPUS:84887114988

VL - 96

SP - 1783

EP - 1789

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -